💰 Inside Oura’s IPO

Editors’ Note: Our website features a healthspan-focused job board, an archive of past newsletters, a growing dictionary of terms we’ve highlighted in previous editions and more to come!

Visit us at: https://stacked-health.com/

Or copy and paste this link to others: {{rp_refer_url}}

Try Factor, America's #1 ready-to-eat meal delivery service.

Made from ingredients you recognize. Whole food. Nothing unnecessary. Let’s eat real.

Get 50% off your first Factor box + Free Breakfast for a year *1 free breakfast item per box for 1 year while subscription active.

Try Factor Now

Oura filed to go public on September 3rd. It will list on Nasdaq under the ticker OURA. The filing makes two claims about the same product:

Both are true, and they sit about forty pages apart in the same document.

What Oura actually sells

Revenue for the nine months ending June 30th was $1.21 billion, up 74% year over year. Hardware accounted for $974.0 million of that. Membership subscriptions accounted for $240.5 million.

So membership is 20% of the business. It was 17.5% last fiscal year and 18.6% the year before that.

Over that same stretch, paid members went from 1.3 million to 5.0 million. The subscriber base nearly quadrupled and the revenue mix barely moved.

The reason is arithmetic. Membership runs $5.99 a month, or roughly $80 a year per member once you account for annual plans. A ring is $349 and up, and Oura sold 3.1 million of them in nine months at an average realized price of about $314.

One ring is worth about four years of membership. So to grow revenue at anything like the current rate, Oura has to keep selling rings, and more of them every quarter than the quarter before.

The rest of the numbers are good. Gross margin improved from 51% to 55%. Operations threw off $328 million in cash. The company is profitable on an operating basis for the first time.

The filing describes Oura as a "health intelligence platform" whose moat is a compounding data asset. The income statement describes a consumer electronics company with a very good attach rate. The platform layer is real and growing. It is not yet what pays the bills, and the filing is honest enough to list dependence on ring sales as a risk factor.

The line Oura is standing on

The FDA has a carve-out for general wellness products. If something is low risk, supports general health, and does not claim to diagnose, treat, or prevent a specific disease, it falls outside active device regulation.

It is a sensible rule. It is what lets a step counter exist without a 510(k) submission, which is the premarket review most medical devices have to clear before they can be sold.

Oura sits inside that carve-out on purpose, and the filing is careful about it. Member testimonials come wrapped in a disclaimer that they are not claims about diagnosing, treating, curing, mitigating, or preventing any disease. The ring is not a medical device and is not intended to be used as one.

Then look at what the product actually ships.

Cardiovascular Age. Blood Pressure Signals. Nighttime Breathing. Symptom Radar. Health Panels, which orders a lab draw for 50 biomarkers and returns the results inside the app.

Behind those features are more than 350,000 people enrolled in an investigational blood pressure study, 50 PhDs and five MDs on staff, a medical advisory board, and a chief medical officer who came from Apple Health.

Oura is a product that is legally a wellness device, staffed and validated like a diagnostics company, used by millions of people with chronic conditions to make decisions about those conditions.

The gap is an asset and a liability at once. Staying on the wellness side keeps Oura fast, with no premarket submissions, no design controls, no waiting on clearance to ship a feature. Crossing over would slow the company down enormously.

But the further real-world use drifts from the regulatory description, the more work that disclaimer is doing.

Someone else owns the metabolic layer

Metabolic health is one of six health pillars Oura names in the filing. It is also the one Oura did not build.

The Glucose feature is defined in Oura's own glossary as a direct integration with the Stelo biosensor by Dexcom. Oura does not make a glucose sensor. It surfaces someone else's readings alongside its own.

Dexcom put $75 million into Oura's Series D before that integration shipped. That is a reasonable way to buy distribution into five million health-attentive households without building a wearable yourself.

The Lilly relationship is more notable and got almost no attention.

The filing discloses an outstanding SAFE, a convertible instrument, held by Eli Lilly and Company that converts to common stock immediately before the offering closes. Separately, LillyDirect is named as a connected care partner, linking Oura's wellness insights to treatment support programs and care pathways.

Read those together. The largest manufacturer of incretin drugs in the world holds a convertible position in the leading consumer health wearable, and that wearable is wired into the manufacturer's own direct-to-consumer distribution platform.

Why You Should Care

Legally, this is a wellness gadget, not a medical device, and Oura says so itself. So if it flags something scary overnight, treat that as a nudge to call a doctor, not a diagnosis.

The bigger thing is that this isn't really an Oura story. It's the first time a company this size has had to put the whole picture in one place: a product regulated like a wellness product, that a majority of its own users say they lean on to manage an actual disease. Every other wearable in this category is doing some version of the same thing. Oura just had to write it down.

Or copy and paste this link to others: {{rp_refer_url}}

Current Referral Count: {{rp_num_referrals}}